Idarubicin

Idamycin

Near Add Your Location

Sorting 8 by

Accepting patients

A Combination of Cladribine, Idarubicin, Cytarabine (CLIA) and Quizartinib for the Treatment of Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS))
  • Tyrosine Kinase (TK) Inhibitor
  • Phase 1/2

Accepting patients

Chemotherapy Plus Venetoclax

Phase II Study of Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With AML, HR MDS, or Myeloid Blast Phase of CML
  • BCL-2 Inhibitor
  • Kinase Inhibitor
  • Tyrosine Kinase (TK) Inhibitor
  • Phase 2

Accepting patients

Gemtuzumab as Part of Chemotherapy

A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim-sndz,Gemtuzumab Ozogamicin and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia
  • Antibody Drug Conjugate (ADC)
  • Hypomethylating Agents (HMA)
  • White Blood Cell Stimulant
  • CD33
  • Phase 2

Accepting patients

Heart Protection w/Dexrazoxane During Chemotherapy

Cardioprotection With Dexrazoxane in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS), Myeloid Blast Phase of Chronic Myeloid Leukemia (CML), Ph+ AML, and Myeloid Blast Phase of Myeloproliferative Neoplasms
  • Chemotherapy
  • Phase 2

Accepting patients

Venetoclax w/ Combination Chemotherapy

A Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive AML Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory AML
  • BCL-2 Inhibitor
  • Chemotherapy
  • Phase 1/2

Accepting patients

PVEK (IMGN632)

Phase 1 Study of FLAG-Ida With Pivekimab Sunirine (PVEK [IMGN632]) for Adults With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
  • Antibody Drug Conjugate (ADC)
  • CD123
  • Phase 1

Accepting patients

Decitabine Combination Therapy Pre-ASCT

Sequential Decitabine in Combination With FLAG-Ida Followed Immediately by Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Cell Transplantation (DEC-FLAG-Ida/RIC) for Adults With Myeloid Malignancies at High Risk of Relapse: A Phase 1/2 Study
  • Allogeneic Stem Cell Transplant
  • Chemotherapy
  • Hypomethylating Agents (HMA)
  • Phase 1/2

Not yet accepting

Combination Chemotherapy Pre-Allogeneic SCT

Pilot Study of FLAG-Ida Followed Immediately by Reduced-Intensity Allogeneic HCT for Adults Age 60 and Older With Newly Diagnosed Adverse-Risk AML or Other High-Grade Myeloid Neoplasm
  • Allogeneic Stem Cell Transplant
  • Chemotherapy
  • Radiation
  • Phase 2